CareDx, Inc (CDNA)
Pre-market:
- Business Wire
CareDx to Report First Quarter 2024 Financial Results
BRISBANE, Calif., April 29, 2024--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2024 after market close on Thursday, May 9, 2024. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- Business Wire
CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., April 19, 2024--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on April 15, 2024, CareDx granted an option to purchase 700,706 shares of CareDx’s common stock (the "Inducement Option") and 487,804 restricted stock units (the "Inducement RSUs" ) to Jo
- Zacks
CareDx (CDNA) Moves 5.5% Higher: Will This Strength Last?
CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
